All articles

Cordyceps and Arrhythmias: A Review of Wang et al., 2022

Cordyceps and Arrhythmias: A Review of Wang et al., 2022

in pictures and a few words

What it is and why it matters

Cordyceps is a mushroom from Chinese folk medicine. This is a summary of trials in which capsules made from its mycelium were added to treatment of heart rhythm problems.

  • One product was studied — Chinese capsules made from mycelium grown in a tank
  • All the trials took place in China
  • The capsules were always added to usual treatment, never given instead of it

Slow and fast rhythm

An arrhythmia is a disturbance of the heart rhythm. With a slow rhythm the heart beats fewer than 60 times a minute, with a fast one more than 100.

  • Slow — for example, when the signal inside the heart is delayed
  • Fast — extra beats, atrial flutter and atrial fibrillation
  • The authors claim the capsules help with both

More people responded

When capsules were added to usual treatment, more people responded to treatment — with both slow and fast rhythm.

  • This held in every group of rhythm problems
  • What counted as a “response to treatment” the article does not say

Pulse with a slow rhythm

With a slow rhythm, the average pulse became faster with the capsules.

  • The lowest pulse did not change significantly
  • With a fast rhythm the pulse did not change significantly
  • The article’s text is stronger than its own numbers — trust the numbers
Slow rhythmTreatment plus capsulesAverage pulse faster

Side effects

The article describes unwanted effects with the capsules as rarer than with usual treatment alone; no serious ones were noted.

  • There were skin allergy, nausea, vomiting, stomach discomfort
  • The trials were small and short — rare effects may not have shown up
  • Compatibility with arrhythmia drugs was not analysed separately in this summary

Important. If skin allergy, nausea, vomiting, stomach discomfort or other reactions appear while taking it — discuss with your doctor whether to continue.

How it might work

The authors only calculated the mechanism on a computer: which proteins linked to heart rhythm the mushroom’s substances might affect.

  • In an old experiment a mushroom extract eased poison-induced arrhythmia in animals
  • The article itself has no experiments on cells or animals
  • The calculation suggests where to look, not whether the remedy helps a person
Mushroom substancesComputer calculationA guess to be tested

How it was taken in trials

In the trials people took 0.5 g of capsules 3 times a day, in one trial 0.25 g 3 times a day, always together with treatment from a doctor.

  • The result applies to these capsules, not to any cordyceps supplement
  • How much caffeine and other substances the capsules contain was not checked
  • Courses in the trials lasted from 2 weeks to a year and a half
Prescribed treatmentDiscuss with a doctorCapsules — only alongside

What the article did not show

“Not shown” does not mean “does not work”: the article simply does not answer these questions.

  • Effect on risk of death, strokes and hospital stays — no data
  • How the capsules act without usual treatment — not studied
  • Which rhythm problems respond better — no comparison

Who should see a doctor first

The decision to take cordyceps for an arrhythmia, and to combine it with medicines, is made together with your doctor.

  • You are being treated for an arrhythmia and take medicines for it
  • Pregnancy, a child, liver or kidney disease — not covered in this article

Important. Do not stop prescribed treatment for the sake of cordyceps: this article did not study that.

In one sentence

One particular Chinese capsule of cordyceps mycelium, added to arrhythmia treatment, gave a signal of benefit in small trials. The mechanism has only been calculated; the decision to take it is made with your doctor.

Frequently asked questions

Not cordyceps in general but Ningxinbao capsules — a standardized traditional Chinese medicine product made from dry mycelium powder of cordyceps grown by liquid submerged fermentation. The dose in the trials was 0.5 g 3 times a day; in one, 0.25 g 3 times a day. The fungal species and strain are not named in the article. In all 19 trials, the capsules were added to routine therapy.

A meta-analysis of 19 small Chinese randomized trials (1,805 patients) showed a signal of benefit: when Ningxinbao capsules were added to routine therapy, the share of “responders” was higher — relative risk (RR) 1.24 in bradyarrhythmias and 1.27–1.40 in tachyarrhythmias. This is the level of a meta-analysis of trials in humans, but what counted as a response to treatment is not disclosed in the article, and there are no data on mortality, strokes, or hospitalizations. This is a basis for rigorous trials, not a proven treatment.

In two trials in humans with bradyarrhythmias, average heart rate (HR) increased with the capsules: standardized mean difference (SMD) 1.10. In tachyarrhythmias, average HR, also in two trials, did not change significantly (SMD −1.14; p = 0.19), although the authors write that cordyceps is “effective in stabilizing heart rates.” Minimal HR in bradyarrhythmias also did not change significantly.

In the three bradyarrhythmia trials that report adverse event incidence as a number, it was 0%, 2.22%, and 0% with the capsules and 19.6%, 7.8%, and 17.9% in the control groups. In tachyarrhythmias, the authors write of fewer cardiovascular and digestive adverse events with the capsules but give no numbers. According to the article's abstract, there were no serious adverse events. Skin allergy, nausea, vomiting, and abdominal discomfort were described in 14 trials; the article does not say in which group. If such symptoms appear while taking the capsules, discuss with your physician whether to continue. The trials were small and lasted from 2 weeks to 1.5 years; rare events may not show up in such samples, and interactions with antiarrhythmic drugs were not analyzed separately. Contraindications, safety in pregnancy, in children, and in liver and kidney disease were not considered in the article.

Only from a computer calculation: matching “compound — protein” and “gene — disease” databases, plus molecular docking. Seven candidate genes (IL6, TNF, TP53, CASP3, CTNNB1, EGF, NOS3) and the PI3K-Akt and adrenergic signaling pathways were identified. The article itself contains no experiments on cells or animals; the authors themselves write that the mechanisms require experimental confirmation.

The article did not study this: in all trials, the capsules were only added to routine treatment, and there are no data on taking them instead of antiarrhythmic drugs. Do not stop prescribed treatment on the basis of this article. Discuss with your physician whether to take cordyceps for arrhythmia and whether to combine it with medications.

No. A single standardized product was studied — Ningxinbao capsules — and the article gives no basis for extending the result to other cordyceps products. The capsule composition and caffeine content were not analyzed in the article.

Share
Follow on TelegramGet new articles, research updates and practical health tips
Читать на русскомЧитати українською

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions. Full disclaimer

Ready to Take Action?

A consultation starts where the article ends: your history, your labs, a plan for your case.

Book consultationAsk a question